MedPath

Utility of a Mobile Application for Young Women With Breast Cancer

Not Applicable
Not yet recruiting
Conditions
Breast Cancer
Cancer Distress
Registration Number
NCT07009093
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.

Detailed Description

This is a prospective, randomized, two stage study. The target population is adult females ≥ 18 and ≤ 45 years of age with breast cancer with a National Comprehensive Cancer Network (NCCN) Distress Thermometer score of distress score ≥ 4. The study will be conducted at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC). The hypothesis is that the social connectivity via the Mighty Pro Application, as well as the educational components available in the application, will decrease patients' cancer-related distress. This study aims to evaluate the feasibility of implementing the Mighty Pro Application and measure its efficacy at reducing distress among young women with breast cancer.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
120
Inclusion Criteria
  • Ability to understand and willingness to sign an IRB-approved informed consent
  • Age ≥ 18 and ≤ 45 years at the time of consent
  • Female
  • Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)
  • Histological confirmation of any type and stage (0-IV) of breast cancer
  • Screening (baseline) NCCN Distress Thermometer score ≥ 4
  • Access to a mobile device for trial purposes and an active email address
  • Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.
  • As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
Exclusion Criteria
  • None

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Stage 1: Feasibility of Implementation of Mighty Pro App26 Weeks

Binary variable indicating if at least one encounter with the application occurred for at least 80% of the weeks during the observation period. At the Participant level, the scale is either 0 (less than 80% utilization of the Mighty Pro App at least once per week during the 26-week observation period) or 1 (80% or greater utilization of the Mighty Pro App App at least once per week during the the 26-week observation period).

Stage 2: Efficacy of the Mighty Pro App26 Weeks

Binary variable indicating if at least a 2-point improvement was achieved from baseline to 26 weeks. At the Participant level, the scale is either 0 (the study participant did not achieve at least a 2-point improvement from baseline to 26 weeks on the distress scale) or 1 (the study participant did achieve at least a 2-point improvement from baseline to 26 weeks on the distress scale). The distress scale ranges from 0 (no distress) to 10 (extreme distress).

Secondary Outcome Measures
NameTimeMethod
Efficacy of the Mighty Pro App in Improving Distress Scores52 Weeks

Binary variable indicating if at least a 2-point improvement was achieved from baseline to 52 weeks. At the Participant level, the scale is either 0 (the study participant did not achieve at least a 2-point improvement from baseline to 52 weeks on the distress scale) or 1 (the study participant did achieve at least a 2-point improvement from baseline to 52 weeks on the distress scale). The distress scale ranges from 0 (no distress) to 10 (extreme distress).

Efficacy of the Mighty Pro App in Improving Distress Scores - Quantitative52 Weeks

Quantitative distress scores collected for each participant and for each time point. For each Participant and each time point a quantitative measure will be collected ranging from 0 (no distress) to 10 (extreme distress).

Trial Locations

Locations (1)

Atrium Health Levine Cancer

🇺🇸

Charlotte, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath